.png?width=320&height=68&name=Portfolia_logo_square_light@2x%20cropped%20(1).png "Portfolia_logo_square_light@2x cropped (1)"){kind=logo}
Thank you to those who attended our event!
The video recording is below.
Learn more about how to invest in Lighthouse Pharma and how you can back companies revolutionizing the active aging & longevity space for returns and impact here.
By 2050, the number of people aged 65 and older with Alzheimer's and dementia is projected to reach 12.7 million. Join Portfolia’s Founder & CEO, Trish Costello in conversation with the CEO of Lighthouse Pharmaceuticals about new advancements helping lessen the severity of Dementia in an aging population.
Lighthouse Pharmaceuticals is backed by Portfolia’s Active Aging & Longevity Fund II. The Fund focuses on answering the question: how do we live healthy and enriching lives into old age, and what choices do people of all ages make today to ensure that they live long, healthy and enriching lives. Lighthouse Pharmaceuticals is changing the way we treat disease, and their approach leverages translational insights and extensive clinical experience to better understand and treat dementia and other disorders.
Trish Costello
Trish Costello is CEO and Founder of Portfolia and Managing Director of Portfolia Funds. Portfolia’s 14 venture capital funds focus on industries that over-index for women, including Active Aging and Longevity, FemTech, Food/AgTech, Green & Sustainability, and Rising America (diversity). Portfolia created the first venture capital fund with a sole focus on women’s health in 2018, and the first led by five women of color partners in 2019. Portfolia is the most active VC firm in the US investing in women’s health and in health conditions that impact women differently, with over 40 investments, and a total of 145 investments across all fields. Trish is internationally recognized for her pioneering work in preparing venture capital investment partners through the prestigious Kauffman Fellows Program, which she created and spun out from the Kauffman Foundation and continues as CEO Emeritus. She was also Founding President of CVE Capital Corp, the holding company of a $1.7 billion venture capital Fund of Funds founded to endow the Kauffman program.
Casey Lynch
Casey Lynch is an entrepreneur and investor with proven background in company building including as the CEO of Lighthouse Pharmaceuticals. Casey is focused on advancement of innovative science including drug and device development, efficient value growth, capital raising, due diligence, and acceleration of translational research into and through the clinic. She is an angel investor and current LP in a variety of venture funds including biotech, creative bioscience, tech, blockchain, women-led and secondary equity as well as several hospitality endeavors.
